October 16, 2013

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Hoff et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d6ca51639f29d8dcab3326 — DOI: https://doi.org/10.1056/nejmoa1304369

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer· 2012 · 214 citations
Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution· 1996 · 627 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors· 2000 · 15,708 citations

Authors

Daniel D. Von Hoff

Thomas J. Ervin

Francis P. Arena

Journals

New England Journal of Medicine

Actions

Institutions

University of Washington

KU Leuven

Seattle University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion